also known as atopic dermatitis, is a non-contagious skin condition that can affect people of all ages. Eczema can range from mild to severe, and is often characterized by red, itchy, dry, and cracked skin.

Areas of the body commonly affected include the face, inside of the elbows, or behind the knees, but eczema can appear anywhere on the body¹. During a “flare,” the symptoms can become painful with an increased urge to itch, resulting in changes in skin color and raw, bleeding blisters. The exact cause of eczema is unknown, but it can develop due to a combination of genes and individual triggers². Examples of triggers can include allergens, cosmetics, detergents, certain fabrics, weather changes (especially dry air), and even stress.

Doctors participating in the EASE clinical study are testing an investigational drug (EP262) to study its safety, tolerability, and effects in patients with eczema.

Eczema can develop by a combination of genetic and environmental factors, resulting in skin barrier dysfunction and dysregulation of the immune system. Mast cells (a type of immune cell present in the skin) have been implicated in the development of eczema skin lesions and severity³. MRGPRX2 is one of the receptors on mast cells, and activation of MRGPRX2 may play a role in eczema. EP262 is an experimental drug designed to block activators of the MRGPRX2 receptor, which may lead to fewer or less severe lesions.

EP262 represents a new, targeted approach to the treatment of eczema that is only available through participation in a clinical study.

If you have eczema you may be interested in learning more about the EASE study.




EASE Study Details

To participate, patients must:

  • Be 18-80 years old.
  • Have a clinical diagnosis of eczema for at least 1 year.
  • Have eczema that covers between 3% to 20% of their body.
  • Not have other active skin diseases associated with chronic itching such as urticaria (hives) or prurigo nodularis.
  • Have had no significant eczema flare-ups for at least 4 weeks before Screening.

what to expect?

  • Screening (1-4 weeks)
    Participants will have 1 study visit where their medical history will be reviewed and tests will be done to see if they qualify for this study.
  • Double-Blind Treatment Period (6 weeks)
    All participants will receive either the investigational drug, EP262, or a placebo as oral capsules to be taken once daily. There is a 2:1 (67%) chance that you will receive the active study drug (EP262). Participants will have 3 study visits during this time for tests and health checks.
  • Follow-Up (4 weeks)
    There will be 1 visit during this period for the study doctor to check on participant health and to have tests.
  • Total participation time is approximately 14 weeks with 5 visits at the study site.

Frequently asked questions about clinical trials

A clinical study, also known as a clinical trial, is designed to learn more about an investigational drug’s ability to treat a specific disease or condition, and what side effects the drug may have. Clinical studies are conducted by experienced and trained medical professionals who monitor the health of participants throughout the study. In addition, an external review board helps to ensure that the study is conducted safely and that the rights and welfare of study participants are protected.

These studies cannot promise any direct benefit. However, the information collected in these studies will help researchers learn more about the study drug (EP262). What researchers learn may help others with this condition in the future. By participating in these studies, you may be helping to advance understanding of this condition and development of a potential new treatment.

All research studies include potential risks. If you are interested in joining this study, you will be given a Participant Informed Consent Sheet to read. This document describes what the study involves, including the known potential risks in more detail. You should review these carefully and discuss them with your study doctor before you decide if you want to take part in this study. There may also be some risks that are not currently known.

Taking part in any study, including the EASE study, is always voluntary. It is your choice. If you meet the eligibility criteria, you can choose to join this study. If you join, you can change your mind and leave the study at any time.

The study drug, assessments and procedures will be provided at no cost to you.

In addition, you may be eligible for travel support and reimbursement of costs related to your study visits. You may also be eligible to receive compensation for completing study visits. Your study doctor and the study staff will explain what support may be available at your study site and how it works.

You can visit any doctor to meet your health needs during enrollment. You should tell other health professionals you see that you are participating in a study. You should also let your study doctor know about any care you receive outside of this study.

Am I Qualified?

Found 0 locations
  • You give permission to Clinago, powered by Innovaderm, to use the personal and health information that you include in this form, for the purpose of evaluating your application to participate in this research study.
  • We will only maintain and process the information you voluntarily provided to us in this form. You authorize Clinago, powered by Innovaderm, to transfer your personal and health information to the clinic you have selected above.
  • Except for the transfer to the clinic you selected, your personal and health information will not be shared with others without your permission, unless permitted or legally required.
  • Please note that your consent does not have an expiration date; however you may withdraw it at any time, noting that any use and/or transfer of your personal and health information made before your withdrawal remains legal and valid.
  • If you want to revoke your consent or if you want to exercise any of your rights (correction, deletion, consulting) or have any inquiry related to our processing of your personal and health information, you must write to: Innovaderm Research Inc., to the attention of its Privacy Officer, at
  • You may also file a complaint with your local data protection authority if you think our processing of your personal and health information violates your right to data protection.
  • You further authorize Innovaderm to keep your personal and health information in our database, so that we can contact you via phone, email, text message or letter, in order to present you with studies that might be of interest to you.
  • For further information, please refer to our Privacy Policy.